Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Jazz Pharmaceuticals plc
www.jazzpharma.comAI Executive Summary
AI-powered analysis of 8-K filing content
Anne O'Riordan, a Class III director at Jazz Pharmaceuticals, announced she will not seek re-election at the 2026 annual shareholder meeting as part of the company's board refreshment strategy. This is a routine succession event with no operational disputes or concerns.
Key Takeaways
Anne O'Riordan will not stand for re-election as Class III director at the 2026 annual meeting
The departure is part of Jazz Pharmaceuticals' planned board refreshment and succession strategy
2 more takeaways